Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage with a target price of 60.67 CNY per share [1]. Core Views - The company is positioned as a leader in the high-end ophthalmic medical device market, with a strong focus on innovation and a comprehensive product matrix that supports growth in various segments, including surgical treatment, myopia control, and vision care [6][10]. - The approval of the "Longjing® PR" intraocular lens in January 2025 is expected to break the import monopoly and enhance the company's competitive edge in the high-end artificial lens market [6][27]. - The increasing demand for ophthalmic treatments driven by an aging population and rising consumer spending is anticipated to accelerate the domestic replacement of imported products [6][34]. Summary by Sections 1. Innovation and Market Position - The company has been deeply engaged in the ophthalmic device sector since its establishment in 2010, becoming a key player in the high-end refractive intraocular lens market [10]. - The product range includes high-end artificial lenses for cataract surgery and myopia control, with significant market penetration achieved through strategic expansions and acquisitions [10][16]. 2. Financial Performance - Revenue projections show a steady increase from 951 million CNY in 2023 to 2,118 million CNY by 2027, with a year-on-year growth rate of 64.1% in 2023 and 48.2% in 2024 [5]. - Net profit is expected to grow from 304 million CNY in 2023 to 563 million CNY by 2027, reflecting a compound annual growth rate of 21.8% [5]. 3. Product Matrix and Growth Drivers - The company’s artificial lens segment is the highest revenue contributor, accounting for 43.86% of total revenue in the first half of 2025, followed by contact lenses at 30.06% [18]. - The introduction of the "Longjing® PR" lens is expected to significantly enhance the product offering and cater to the growing demand for high-quality vision correction solutions [27][34]. 4. Market Trends and Opportunities - The aging population in China is projected to increase the number of cataract patients, thereby expanding the market for high-end artificial lenses [34]. - The company is also capitalizing on the growing myopia prevention market, with its "Punotong®" orthokeratology lenses gaining traction under national health initiatives [47]. 5. Competitive Landscape - The company has established a strong competitive position through its innovative product offerings and strategic acquisitions, which have allowed it to build a comprehensive product line that meets diverse consumer needs [6][10]. - The recent approval of its products underlines the company's commitment to innovation and its ability to compete effectively against established international brands [27][34].